ClinicalTrials.gg
CompletedNCT00723983NP101-011Updated Feb 3, 2016

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

A Phase 1 interventional study of Sumatriptan succinate and NP101 Study Patch in Migraine Disorders, sponsored by NuPathe Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-03.

Sponsored by NuPathe Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Teva Pharmaceutical Industries, Ltd..

Enrollment
18th of 19
23 · median 353
Started
2008
with 1 other
Phase 1
3 of 20
none open now
Registered
3rd of 20
by date

Among the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd., this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2008, is one of 3 in phase 1, and was the 3rd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Migraine Disorders, anywhere →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female subjects, between the ages of 18 to 65 years.
  • Subjects with a diagnosis of migraine headache, with or without aura, as defined in the ICHD-II, and the diagnosis was made before the age of 50.
  • The majority of a subject's headaches during a migraine attack are moderate to severe in intensity.
  • Subject has history of regularly occuring migraines, accompanied by nausea or vomiting.
  • Subject has at least one year history of migraine based upon subject testimony.
  • Subject will be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, and laboratory profile.
  • Subjects must voluntarily sign and date and agreement approved by an IRB.
  • Subject must have a negative drug screen and re-screen.
  • Female subjects of must have a negative pregnancy test at Screening and Re-Screening.
  • Subject has two acceptable patch application sites.

Exclusion criteria

Exclusion Criteria:

  • Subject has or plans to start stop, or change treatment (including dose change) of any medication within one month prior to the subject screening date and through the end of study.
  • Subject has less than 2 migraines per month or subject has more than 15 headache days/month for any of the 3 months prior ot screening.
  • Subject who has suspected or confirmed cardiovascular disease that contraindicates study participation.
  • Subject has history of epilepsy or conditions associated with lower seizure threshold.
  • Subject with Raynaud's disease.
  • Subject with hemiplegic or basilar migraine.
  • Subject with a current diagnosis of major depressive disorder.
  • Subject who has taken non-triptan serotonergic drugs including SSRI's, SNRI, TCAs or MAOI's or preparations containing St. John's Wort within month prior to screening and/or is planning to start any of these medications during the study and through the End of Study Visit.
  • Subject is unwilling to discontinue use of PD5 inhibitors (eg. Viagra, Levitra, Cialis) from screening through End of Study Visit.
  • Subject with a history of significant allergy or to any component of the NP101 study patch.
  • Subject who has any generalized skin irritation or disease including eczema, psoriasis, melanoma, acne or contact dermatitis.
  • Subject has a positive test result for , or is known to be positive.
  • Subjects with moderate or severe hepatic dysfunction defined as /AST or SGPT/ALT ≥ 2 times the , or alkaline phosphatase or total ≥ 1.5 times the upper limit of normal range or if in the opinion of the investigator, the subject's history, physical examination or other laboratory tests suggest hepatic dysfunction.
  • Female subjects who are pregnant, breast feeding, or if not of , is not using or is unwilling to use an effective form of during the study and for a period of 30 days following final dosing.
  • Subjects with a known history of tolerability issues with sumatriptan.
  • Subject who is considered by the investigator or NuPathe to be an unsuitable candidate for this study.
  • Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or dependence.
  • Subject has participated in a clinical study within 30 days of Screening or is planning to participate in another clinical study.
  • Subject has abnormal labs, vital signs or
  • Subject is electrically sensitive or who has an implantable electronic device.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Active comparator
    Period 1

    Subject dosed with oral sumatriptan succinate during an acute migraine attack.

    Drug: Sumatriptan succinate

  • Active comparator
    Period 2

    Subject dosed with oral sumatriptan during a non-migraine period.

    Drug: Sumatriptan succinate

  • Experimental
    Period 3 and Period 6

    Subject dosed with NP101 during an acute migraine attack.

    Drug: NP101 Study Patch

  • Experimental
    Period 4 and Period 5

    Subject dosed with NP101 study patch during a non-migraine period.

    Drug: NP101 Study Patch

Interventions

06

What researchers measure

Primary outcomes

  1. Compare the pharmacokinetics of NP101 with a currently approved formulation of Imitrex in migraine subjects during an acute migraine attack and during a non-migraine period.

    Time frame: PK samples at pre and 0.25, 0.5, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12 and 24 hours post each dose/period for Periods 1, 2, 3, and 4 [24 hour PK will not be done for Periods 5 and 6]

07

Study locations

1 site
  • MD Clinic
    Hallandale Beach, Florida 33009, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2008
First posted
Jul 29, 2008
Start
Nov 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Last update
Feb 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00723983
Lead sponsor
NuPathe Inc.
Responsible party
Sponsor
First posted
Jul 29, 2008
Start date
Nov 2008
Primary completion
Sep 2009
Completion
Sep 2009
Last update
Feb 3, 2016

Study contacts

Kerri L Wilks, MD, CPI
principal investigator · MD Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement · Sumatriptan

Start the discussion